Technical Analysis for LYEL - Lyell Immunopharma, Inc.

Grade Last Price % Change Price Change
D 2.08 -3.70% -0.08
LYEL closed down 3.7 percent on Monday, March 18, 2024, on 59 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Mar 26
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
200 DMA Resistance Bearish -3.70%
Fell Below 50 DMA Bearish -3.70%
Wide Bands Range Expansion -3.70%
Gapped Up Strength -3.70%
Oversold Stochastic Weakness -3.70%
Fell Below 200 DMA Bearish -5.88%

   Recent Intraday Alerts

Alert Time
Down 5% about 21 hours ago
Down 3% about 22 hours ago
Fell Below Previous Day's Low about 22 hours ago
Down 2 % about 22 hours ago
Down 1% about 22 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Lyell Immunopharma, Inc. Description

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers, as well as ovarian and other solid tumors; LYL845, an IV administered autologous TIL therapy for multiple solid tumors; and NY-ESO-1, a T cell product candidate for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Biology Solid Tumors Stem Cell Cell Biology Non Small Cell Lung Cancer Cloning Induced Stem Cells Treatment Of Non Small Cell Lung Cancer Synovial Sarcoma Developmental Biology

Is LYEL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.97
52 Week Low 1.32
Average Volume 1,007,201
200-Day Moving Average 2.23
50-Day Moving Average 2.17
20-Day Moving Average 2.48
10-Day Moving Average 2.35
Average True Range 0.21
RSI (14) 42.86
ADX 21.87
+DI 20.25
-DI 22.86
Chandelier Exit (Long, 3 ATRs) 2.61
Chandelier Exit (Short, 3 ATRs) 2.41
Upper Bollinger Bands 3.03
Lower Bollinger Band 1.93
Percent B (%b) 0.14
BandWidth 44.39
MACD Line 0.01
MACD Signal Line 0.09
MACD Histogram -0.078
Fundamentals Value
Market Cap 523.89 Million
Num Shares 252 Million
EPS -0.76
Price-to-Earnings (P/E) Ratio -2.74
Price-to-Sales 9.35
Price-to-Book 0.62
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.29
Resistance 3 (R3) 2.30 2.25 2.26
Resistance 2 (R2) 2.25 2.19 2.24 2.24
Resistance 1 (R1) 2.16 2.16 2.14 2.15 2.23
Pivot Point 2.11 2.11 2.09 2.10 2.11
Support 1 (S1) 2.02 2.05 2.00 2.01 1.93
Support 2 (S2) 1.97 2.02 1.96 1.92
Support 3 (S3) 1.88 1.97 1.91
Support 4 (S4) 1.87